These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37559375)

  • 1. An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox.
    Tomita N; Terada-Hirashima J; Uemura Y; Shimizu Y; Iwasaki H; Yano R; Suzuki T; Saito S; Okumura N; Sugiura W; Ohmagari N; Ujiie M
    Hum Vaccin Immunother; 2023 Aug; 19(2):2242219. PubMed ID: 37559375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of the Smallpox Vaccine for Postexposure Prophylaxis in Monkeypox: Protocol for an Open-Labeled, Single-Armed Study.
    Yano R; Terada-Hirashima J; Uemura Y; Tomita N; Shimizu Y; Iwasaki H; Okumura N; Suzuki T; Saito S; Ujiie M; Sugiura W; Ohmagari N
    JMIR Res Protoc; 2023 Aug; 12():e46955. PubMed ID: 37624623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Freeze-dried live attenuated smallpox vaccine prepared in cell culture "LC16-KAKETSUKEN": Post-marketing surveillance study on safety and efficacy compliant with Good Clinical Practice.
    Nishiyama Y; Fujii T; Kanatani Y; Shinmura Y; Yokote H; Hashizume S
    Vaccine; 2015 Nov; 33(45):6120-7. PubMed ID: 26455406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the Immunogenicity and Safety of a Smallpox Vaccine to Monkeypox in Healthy Japanese Adults: A Single-Arm Study.
    Tomita N; Morino E; Terada-Hirashima J; Uemura Y; Shimizu Y; Saito S; Suzuki T; Okumura N; Iwasaki H; Ebihara H; Shimojima M; Sugiura W; Ohmagari N; Ujiie M
    Life (Basel); 2023 Mar; 13(3):. PubMed ID: 36983942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
    Ladhani SN; Dowell AC; Jones S; Hicks B; Rowe C; Begum J; Wailblinger D; Wright J; Owens S; Pickering A; Shilltoe B; McMaster P; Whittaker E; Zuo J; Powell A; Amirthalingam G; Mandal S; Lopez-Bernal J; Ramsay ME; Kissane N; Bell M; Watson H; Ho D; Hallis B; Otter A; Moss P; Cohen J
    Lancet Infect Dis; 2023 Sep; 23(9):1042-1050. PubMed ID: 37336224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mpox: Rapid Evidence Review.
    Saguil A; Krebs L; Choe U
    Am Fam Physician; 2023 Jul; 108(1):78-83. PubMed ID: 37440743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smallpox vaccination and adverse reactions. Guidance for clinicians.
    Cono J; Casey CG; Bell DM;
    MMWR Recomm Rep; 2003 Feb; 52(RR-4):1-28. PubMed ID: 12617510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-exposure vaccine effectiveness and contact management in the mpox outbreak, Madrid, Spain, May to August 2022.
    Montero Morales L; Barbas Del Buey JF; Alonso García M; Cenamor Largo N; Nieto Juliá A; Vázquez Torres MC; Jiménez Bueno S; Aragón Peña A; Gil Montalbán E; Íñigo Martínez J; Alonso Colón M; Arce Arnáez A;
    Euro Surveill; 2023 Jun; 28(24):. PubMed ID: 37318762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Diagnosis, Prevention, and Treatment of mpox (Monkeypox): A Review for Dermatologists.
    Gupta AK; Talukder M; Rosen T; Piguet V
    Am J Clin Dermatol; 2023 Jul; 24(4):541-556. PubMed ID: 37106278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Post-Eradication Smallpox Vaccine as an Mpox Vaccine: A Systematic Review with Meta-Analysis.
    Malone SM; Mitra AK; Onumah NA; Brown A; Jones LM; Tresvant D; Brown CS; Onyia AU; Iseguede FO
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mpox and children - a Swedish perspective].
    Alfvén T; Arthur Rhedin S; Mia Ekström A; Elfving K; Sondén K
    Lakartidningen; 2023 Jun; 120():. PubMed ID: 37334572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for the Re-Emerging Human Monkeypox Virus.
    Lee W; Kim YJ; Lee SJ; Ahn DG; Kim SJ
    J Microbiol Biotechnol; 2023 Aug; 33(8):981-991. PubMed ID: 37519276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human monkeypox virus in the shadow of the COVID-19 pandemic.
    Khamees A; Awadi S; Al-Shami K; Alkhoun HA; Al-Eitan SF; Alsheikh AM; Saeed A; Al-Zoubi RM; Zoubi MSA
    J Infect Public Health; 2023 Aug; 16(8):1149-1157. PubMed ID: 37269693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mpox outbreak in the Netherlands, 2022: public health response, characteristics of the first 1,000 cases and protection of the first-generation smallpox vaccine.
    van Ewijk CE; Miura F; van Rijckevorsel G; de Vries HJ; Welkers MR; van den Berg OE; Friesema IH; van den Berg PR; Dalhuisen T; Wallinga J; Brandwagt D; van Cleef BA; Vennema H; Voordouw B; Koopmans M; van der Eijk AA; Swaan CM; Te Wierik MJ; Leenstra T; Op de Coul E; Franz E; ;
    Euro Surveill; 2023 Mar; 28(12):. PubMed ID: 36951783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutics for treating mpox in humans.
    Fox T; Gould S; Princy N; Rowland T; Lutje V; Kuehn R
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD015769. PubMed ID: 36916727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough Infections after Postexposure Vaccination against Mpox.
    Thy M; Peiffer-Smadja N; Mailhe M; Kramer L; Ferré VM; Houhou N; Tarhini H; Bertin C; Beaumont AL; Garé M; Le Pluart D; Perrineau S; Rahi M; Deconinck L; Phung B; Mollo B; Cortier M; Cresta M; De La Porte Des Vaux C; Joly V; Lariven S; Rioux C; Somarriba C; Lescure FX; Charpentier C; Yazdanpanah Y; Ghosn J
    N Engl J Med; 2022 Dec; 387(26):2477-2479. PubMed ID: 36477495
    [No Abstract]   [Full Text] [Related]  

  • 17. Mimics of Monkeypox: Considerations for the emergency medicine clinician.
    Long B; Liang SY; Carius BM; Chavez S; Gottlieb M; Koyfman A; Brady WJ
    Am J Emerg Med; 2023 Mar; 65():172-178. PubMed ID: 36640626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress and prospects on vaccine development against monkeypox infection.
    Saadh MJ; Ghadimkhani T; Soltani N; Abbassioun A; Daniel Cosme Pecho R; Taha A; Jwad Kazem T; Yasamineh S; Gholizadeh O
    Microb Pathog; 2023 Jul; 180():106156. PubMed ID: 37201635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe mpox (formerly monkeypox) disease in five patients after recent vaccination with MVA-BN vaccine, Belgium, July to October 2022.
    Berens-Riha N; De Block T; Rutgers J; Michiels J; Van Gestel L; Hens M; ; Kenyon C; Bottieau E; Soentjens P; van Griensven J; Brosius I; Ariën KK; Van Esbroeck M; Rezende AM; Vercauteren K; Liesenborghs L;
    Euro Surveill; 2022 Dec; 27(48):. PubMed ID: 36695462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study.
    Bertran M; Andrews N; Davison C; Dugbazah B; Boateng J; Lunt R; Hardstaff J; Green M; Blomquist P; Turner C; Mohammed H; Cordery R; Mandal S; Campbell C; Ladhani SN; Ramsay M; Amirthalingam G; Bernal JL
    Lancet Infect Dis; 2023 Jul; 23(7):828-835. PubMed ID: 36924787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.